TPU scientists, together with their colleagues from Moscow, managed to synthesize molecule for the diagnosis and treatment of a new generation of prostate cancer. This compound aims to detect two types of cancer biobelirts, unlike the existing predecessors. This “Gazeta.ru” was told about the Russian Federation at the Ministry of Education and Science.
In order for the drug to find and treat cancer simultaneously, the radioactive isotopes of different tasks “stick” to a molecule. In total, there are two such compounds for prostate cancer in the world. Both compounds can detect prostate-specific membrane antigen-a kind of biobelirt of this disease. Oncologists determine the localization and volume of neoplasms.
“As a rule, there is no biobelirt on the surface of a patient, but a few at once. And now we are looking for a new molecule-asnov for the drug, not at once, but two biobelirts. Larkina, senior researcher at the Oncotherapy Research Center.
As one of the candidates for a new foundation, scientists are now a compound – the derivative of urea and amino acids. The synthesis of a similar molecule lasts two to four weeks and occurs at eight or more stages.
The new molecular isotop lutetia-177, which is used in therapeutic radiosesmas, is a scientists. It has proven that laboratory studies are good stability and high efficiency.
Iz We are at the beginning of the work where we face the task of achieving a sustainable and functional connection to talk about the emergence of a new drug. In total, we plan to determine the connection with the best features, to evaluate toxicity and to go to clinical trial, or he says.
It was before Name Ways to moisturize your eyes without drops.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.